PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

zaleplon Side Effects

The reactions most often reported to the FDA for zaleplon (also sold as Sonata), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

1,538
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of zaleplon come from 1,538 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 1,538 reports to the FDA Adverse Event Reporting System (FAERS) for zaleplon (Sonata): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

1,538

Reports Mentioning Death

173

11.2% of reports — not proof the medicine caused the death

Hospitalizations

338

22.0% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

NAUSEA
111
COMPLETED SUICIDE
88
INSOMNIA
80
HEADACHE
79
FALL
77
ANXIETY
76
PAIN
72
FATIGUE
69
DIZZINESS
58
DIARRHOEA
57
DEPRESSION
50
MALAISE
49
VOMITING
49
CHRONIC KIDNEY DISEASE
46
SOMNOLENCE
46
FEELING ABNORMAL
45
TOXICITY TO VARIOUS AGENTS
44
DYSPNOEA
40

Who Reports Side Effects

Gender Distribution

Female 979 (68%)
Male 462 (32%)
Unknown 8

Age Distribution

0-17 15 (2%)
18-44 200 (23%)
45-64 406 (46%)
65-74 159 (18%)
75+ 99 (11%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 173 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
COMPLETED SUICIDE 88
TOXICITY TO VARIOUS AGENTS 29
DEATH 27
CARDIAC ARREST 10
OVERDOSE 9
INTENTIONAL PRODUCT MISUSE 8
PNEUMONIA 8
SUSPECTED SUICIDE 6
INSOMNIA 5
RENAL FAILURE 5
RESPIRATORY FAILURE 5
CHRONIC KIDNEY DISEASE 4
ABNORMAL BEHAVIOUR 3
ACUTE KIDNEY INJURY 3
ASPIRATION 3
BRAIN OEDEMA 3
DEPRESSION 3
DRUG TOXICITY 3
FALL 3
MULTIPLE ORGAN DYSFUNCTION SYNDROME 3

Reactions in Hospitalization Reports

Top reactions in 338 reports where hospitalization was an outcome.

Reaction Reports
FALL 33
PNEUMONIA 22
ACUTE KIDNEY INJURY 21
NAUSEA 19
RENAL FAILURE 19
URINARY TRACT INFECTION 19
CHRONIC KIDNEY DISEASE 17
HYPOTENSION 17
INSOMNIA 17
SOMNOLENCE 17
PAIN 16
TOXICITY TO VARIOUS AGENTS 16
ANXIETY 15
COMPLETED SUICIDE 15
DYSPNOEA 15
SINUSITIS 15
VOMITING 15
DIZZINESS 14
OVERDOSE 14
DIARRHOEA 13

Compare zaleplon vs eszopiclone →

What the FAERS Data Reveals About zaleplon Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 1,538 voluntary reports linked to zaleplon and its brand equivalents (Sonata), spanning 2004 through 2025. Of those, 173 (11.2%) listed death as an outcome and 338 (22.0%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 68% were female and 32% male; age distribution skews toward 45-64, with 406 reports in that bracket. The single most reported reaction is nausea with 111 submissions, followed by completed suicide and insomnia.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.